Enrichment of Cells with Cancer Stem Cell-Like Markers in Relapses of Chemoresistant Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma
Enrichment of Cells with Cancer Stem Cell-Like Markers in Relapses of Chemoresistant Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma
复制标题
DOI：
10.1159/000445118
复制
发表时间：
2016-01-01
期刊：
影响因子：
3.5
通讯作者：
Domingo-Domenech, Josep
中科院分区：
文献类型：
--
作者：
Grau, Juan J.;Mesia, Ricard;Domingo-Domenech, Josep
背景：头颈鳞状细胞癌（HNSCC）患者对化疗和放疗表现出不同的反应。一种解释可能是干细胞样细胞个体比率的差异。方法：我们纳入了患有 HNSCC 且肿瘤进展或复发的患者。在初次化疗之前和之后获得肿瘤样本，并对 CD44、HLA I 类 (HLA-I)、全细胞角蛋白和磷酸化表皮生长因子受体 (p-EGFR) 进行免疫组织化学分析。评估第一个和第二个样本之间的表达差异。结果：第一个和第二个样本之间的表达变化如下：CD44 增加 14.67%（95% 置信区间，CI：6.94 至 22.40；p < 0.01）； HLA-I 下降 16.72%（95% CI：-23.87 至 -9.47；p < 0.01）；全细胞角蛋白下降 24.91%（95% CI：-32.8 至 -17.7；p < 0.01），p-EFGR 表达下降 12.30%（95% CI：-20.61 至 -3.98；p < 0.005）。结论：在 HNSCC 患者中，与原发肿瘤相比，复发肿瘤中具有干细胞样标志物的细胞富集。在制定治疗策略时应考虑这一发现。 (C) 2016 S. Karger AG，巴塞尔
Background: Patients with head and neck squamous cell carcinoma (HNSCC) present different responses to chemotherapy and radiotherapy. One explanation may be the differences in the individual rates of stem cell-like cells. Methods: We included patients with HNSCC and tumor progression or relapse. Tumor samples were obtained before and after primary chemotherapy, and immunohistochemical analyses were performed for CD44, HLA class I (HLA-I), pancytokeratin, and phosphorylated epidermal growth factor receptor (p-EGFR). Differences in expression between the first and second specimens were assessed. Results: Expression between the first and second specimens varied as follows: CD44 increased by 14.67% (95% confidence interval, CI: 6.94 to 22.40; p < 0.01); HLA-I decreased by 16.72% (95% CI: -23.87 to -9.47; p < 0.01); pancytokeratin decreased by 24.91% (95% CI: -32.8 to -17.7; p < 0.01), and p-EFGR expression decreased by 12.30% (95% CI: -20.61 to -3.98; p < 0.005). Conclusions: Among patients with HNSCC, there is an enrichment of cells with stem-like markers in relapsed tumors when compared with the primary tumor. This finding should be considered when developing treatment strategies. (C) 2016 S. Karger AG, Basel